Participated · Equity · Jul 2026

TidalSense develops an AI-powered diagnostic test, N-Tidal Diagnose, that captures a CO₂ waveform via a handheld device during normal breathing and analyzes it with AI models. The test requires patients to breathe into the device for around 75 seconds and TidalSense says its models have been trained on more than 2.5 million patient breaths. The company states that tests can be performed in under five minutes and that clinicians can see four to six patients an hour versus roughly one per hour with traditional spirometry. TidalSense says any healthcare professional can be trained to use the device in about 10 minutes without specialist qualifications. It launched the test on the NHS last year and plans to scale rollout across the NHS, expand into Europe and enter the US market. The company is led by CEO Dr. Ameera Patel and was founded in 2013.

Led · Series B · Jan 2026

Bactolife is a Danish startup creating a new class of gut-health ingredients called binding proteins that latch onto and flush out harmful bacterial metabolites without disrupting the microbiome. Drawing inspiration from camelid immunoglobulin fragments, the firm engineers microbes via precision fermentation to produce vegan, allergen-free, heat- and pH-stable proteins effective at 100–200 mg doses. Its first two proteins are expected to receive self-affirmed GRAS status in the U.S. in Q1 and will debut this year under the “Helm” brand in dietary supplements and functional foods, with subsequent rollouts planned for Asia and Europe. The company is running human clinical studies in the U.S. and U.K. and has already secured several commercial partners interested in standalone or combined formulations with pre- and probiotics. Over the next three to five years, Bactolife intends to build a broad portfolio of binding proteins addressing common gut-health concerns and to supply both human nutrition and animal feed markets. A recently raised €30 million+ ($35 million+) Series B round will finance clinical validation, regulatory filings, manufacturing scale-up and commercialization. The article did not disclose any current revenue or user metrics.

Participated · Equity · Feb 2025

Pendulum is a Washington, DC–based company focused on real-time planning for the global supply chain. Its AI platform predicts demand, optimizes supply, and ensures asset visibility across industries including retail, healthcare, and national security. The system continuously improves itself and is built on foundation models for supply and demand developed over years of MIT-grade R&D. Led by CEO Benjamin Thelonious Fels, the company also added Jean-François Gagné as Chief Strategy and Product Officer. Pendulum has raised $22M in total funding, split between $11M in non-dilutive R&D capital and $11M in venture capital. The company intends to use the funds to expand operations and accelerate development efforts.

Led · Series A · Jan 2025

Oxford Cancer Analytics (OXcan) is a medtech company developing protein-based blood tests for early cancer detection using advanced proteomics, explainable machine learning, and AI. Its core product is a protein-based liquid biopsy intended to identify molecular signatures in high-risk lung cancer patients with high accuracy and localization capacity. OXcan leverages a diverse global biobank and, since 2023, has partnered with over 20 healthcare centers across three continents to develop and deploy its technology. The company has achieved ISO13485 certification and describes the test as affordable, minimally invasive, and suitable for routine population screening. OXcan plans to use new funding to develop and globally commercialize its next-generation lung cancer blood tests. It recently raised US$11 million in a Series A and appointed Dr. Heinrich Roder as Senior Vice President of R&D to advance its lung cancer blood test toward deployment.

Led · Series A · Oct 2024

OncoLens develops oncology-focused AI that extracts key insights from structured and unstructured clinical, molecular, and lab data to identify patients who may have missed treatment-defining diagnostics or therapies in real time. Its collaboration solutions help cancer centers coordinate next steps to ensure timely, multidisciplinary action. The company serves national cancer institutes, academic medical centers, and community-based integrated delivery networks, and also operates internationally after launching in the EMEA region in 2022. With a growing customer base, OncoLens launched the OncoLens Research Network to partner with life‑science commercial, real‑world evidence, and clinical development teams to bring trials and quality-improvement initiatives to its centers. For life‑science partners the company offers access to a diverse, community-focused network to address RWE, diversity and inclusion in trials, and to find patients with rare genomic alterations. The company is led by CEO Anju Mathew and recently raised capital to expand its development efforts. OncoLens provides an integration and collaboration platform to cancer centers that enables multidisciplinary cancer care across the continuum. Through a streamlined, secure HIPAA-compliant infrastructure it drives intra-enterprise, community, and network participation in multidisciplinary care planning, tracking, and delivery. Patients can collaborate on treatment plans, track quality for accreditation, and align to care pathways, while health systems can maximize clinical trial participation and referral streams. The company supports creation of centers of excellence that can be leveraged for patient care and provider education. It serves more than 200 cancer centers in the U.S. and has clients in the larger EMEA region. Led by CEO Anju Mathew, OncoLens intends to use the new funds to expand domestic and global footprint into rural communities and low- and middle-income countries to improve capacity, access, and diversity in research. The financial terms of the investment were not disclosed. OncoLens offers a collaborative, HIPAA-compliant tumor board and cancer treatment planning platform that aggregates patient-specific data across EMR, clinical, and genetics systems and provides decision support. Its software includes virtual tumor board technology, workflow automation, survivorship care planning, and clinical decision support to standardize care and improve efficiencies. The platform automatically identifies patient-specific clinical trials at a facility or affiliates and surfaces relevant NCCN/ASCO guidelines and the latest research to support care teams. OncoLens is used or being implemented across several National Cancer Institute-designated cancer centers and large U.S. healthcare delivery networks, and currently serves more than 8,000 cancer care providers. The company has received market recognition with studies showcased in professional journals and conferences. Management says the new funding will accelerate product development and market expansion as it builds on its position in tumor board and treatment-planning software. OncoLens develops tumor board and cancer treatment planning software that consolidates clinical, radiological, and pathological data to streamline multidisciplinary case discussions. Its platform includes an intelligent workflow engine that automates accreditation and quality reporting, facilitates survivorship care planning, and supports more informed clinical decision-making. The company uses proprietary algorithms to reduce clinician workload by matching patients with relevant clinical trials and potential targeted therapies. OncoLens currently serves several large integrated delivery networks (IDNs) and hospitals across the U.S. Led by co-founder and CEO Anju Mathew, the company plans to expand its product capabilities and grow sales and marketing resources using new funding. The recent financing strengthens its position to scale adoption among health systems. OncoLens offers a Software-as-a-Service platform that enables diverse, multispecialty cancer care teams to collaborate on individual patient treatment plans. The platform provides cancer-specific clinical decision support, helps programs track and implement nationally approved quality metrics, and surfaces applicable clinical trials. It consolidates case data and workflows to streamline tumor board management and survivorship care planning, reducing the manual data-aggregation burden described in the article. OncoLens says its solution decreases a cancer center’s workload and saves resources by standardizing discussions and integrating multiple workflows. The company recently closed a $1.35 million seed round to fund strategic growth and product expansion. OncoLens is part of Georgia Tech’s ATDC Accelerate portfolio and has received industry recognitions, including an “Exceptional Research Award” from the Academy of Oncology Nurse Navigators.